Timothy Coughlin

Timothy Coughlin (board member) discloses dealings in 5 companies, chiefly Travere Therapeutics, Inc., ADC Therapeutics SA and aTYR PHARMA Inc. In total, 20 filings cover trades dated from 14 May 2021 to 12 June 2026.

Market trades split into 1 purchase (€81k) and 2 sales (€31k). No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 13 share grants and 3 option exercises. Since January 2026: no purchases and 1 sale on the market.

On 16 June 2026 came the latest disclosure, an option exercise in Travere Therapeutics, Inc. The latest purchase dates back some time: it was published 867 days ago, on 3 June 2024. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.